Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Journal of NeurochemistryOpen Access

Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain‐Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaciej DulewiczJHJörg Hanrieder

Discussion

Loading...

Member takes

Overview

Observational analysis evaluates diagnostic accuracy of plasma phosphorylated tau in Alzheimer's Disease, suggesting its utility in screening.

Key Points

  • Plasma phosphorylated tau biomarkers show promise for diagnosing Alzheimer's disease.
  • p-tau217 demonstrated a diagnostic accuracy with an AUC of 0.954, crucial for early detection.
  • Plasma levels were measured using Single Molecule Array assays across 160 memory clinic patients.
  • Elevated p-tau levels indicate neurochemical changes in Alzheimer's Disease, supporting diagnostic accuracy.

Cite This Study

Dulewicz et al. (2025) studied this question.

synapsesocial.com/papers/6930dc92ea1aef094cca2929https://doi.org/10.1111/jnc.70313
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer’s disease: a systematic review and meta-analysis2026
  2. 2Analytical considerations and clinical utility of plasma phosphorylated Tau2172025
  3. 3From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer’s Disease: A Fagan Nomogram-Based Meta-Analytic Study2026
  4. 4Brain‐derived plasma p‐tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change2026
  5. 5Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice2026